BCAX
NASDAQBicara Therapeutics Inc.
Price$20.11+0.38 (+1.90%)
02:15 PM07:00 PM
News · 26 weeks82-68%
2025-12-142026-06-07
Mix3990d
- Insider14(36%)
- SEC Filings10(26%)
- Other8(21%)
- Earnings3(8%)
- Analyst2(5%)
- Offering2(5%)
Latest news
25 items- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERChief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCCAt a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive Company to h
- INSIDERChief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERPresident and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- SECSEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on
- INSIDERSEC Form 4 filed by Chief Medical Officer Schelman William4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schelman William3 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 10-Q filed by Bicara Therapeutics Inc.10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)
- ANALYSTGuggenheim initiated coverage on Bicara Therapeutics with a new price targetGuggenheim initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRBicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateStudy to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up data from Phase 1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC patients to be presented at ASCO 2026 Bill Schelman, M.D., Ph.D., EVP, Clinical Development promoted to Chief Medical Officer, and David Raben, M.D., Chief Medical Officer transitioned to serve as a Senior Executive Advisor to the company Chris Sarchi appointed as Chief Commercial Officer BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX) today announce
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- PRBicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ETBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast,
- INSIDERChief Medical Officer Raben David exercised 5,500 shares at a strike of $3.79 and sold $125,830 worth of shares (5,500 units at $22.88) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form DEFA14A filed by Bicara Therapeutics Inc.DEFA14A - Bicara Therapeutics Inc. (0002023658) (Filer)
- SECSEC Form DEF 14A filed by Bicara Therapeutics Inc.DEF 14A - Bicara Therapeutics Inc. (0002023658) (Filer)
- INSIDERSEC Form 4 filed by Hyep Ivan4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Mazumdar Claire4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
BCAX FAQ
6 questionsWhere does BCAX stock trade?
Bicara Therapeutics Inc. (BCAX) is listed on NASDAQ.What sector and industry is BCAX in?
Bicara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bicara Therapeutics Inc. go public?
Bicara Therapeutics Inc. (BCAX) completed its IPO in 2024.What are analysts saying about BCAX?
Bicara Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $4200.00 price target on 2026-05-11.What companies are similar to BCAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BCAX side-by-side with any of them on Quantisnow.How can I track BCAX on Quantisnow?
Quantisnow aggregates Bicara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCAX to receive live email and push alerts on every new disclosure.